Publications

#2022-250

Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model

SCHUBERT W (a), TERJUNG C (a), RAFIQUE A (b), ROMANO C (b), ELLINGER P (a), RITTENHOUSE K (c)

Trans. Vis. Sci. Tech. 2022;11(10):36. doi: 10.1167/tvst.11.10.36 (collaboration)

(a) BAYER AG, Wuppertal, Germany – (b) REGENERON PHARMACEUTICALS, Inc., Tarrytown, NY, USA – (c) BAYER CONSUMER CARE AG, Basel, Switzerland

⇒ Article

#2022-246

Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders

OBASANMI G (a), NESBIT MA (a), COBICE D (a), MACKAY L (b), MCGIMPSEY S (c), WAPPETT M (d), CRANSTON AN (d), MOORE TCB (a)

Ophthalmol. Sci. 2022; 2, 2, 100150. doi: 10.1016/j.xops.2022.100150 (collaboration)

(a) BIOMEDICAL SCIENCES RESEARCH INSTITUTE, Ulster University, Coleraine, United Kingdom - (b) Scottish Instrumentation and Research Centre for Advanced Mass Spectrometry (SIRCAMS), University of Edinburgh, Edinburgh, United Kingdom - (c) Mater Infirmorum Hospital, Belfast, United Kingdom - (d) ALMAC DISCOVERY Ltd., Belfast, United Kingdom

⇒ Article

#2021-237

A rare natural lipid induces neuroglobin expression to prevent amyloid oligomers toxicity and retinal neurodegeneration

OAMEN HP (a), ROMERO N (a), KNUCKLES P (b), SAARIKANGAS J (c), DONG Y (d), CAUDRON F (a)

Aging Cell. 2022;21(7):e13645. doi: 10.1111/acel.13645 (collaboration)

(a) SCHOOL OF BIOLOGICAL SCIENCES, London, UK, (b) FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland, (c) HELSINKI INSTITUTE OF LIFE SCIENCE, Helsinki, Finland; Research Programme in Molecular and Integrative Biosciences, University of Helsinki, Finland; Neuroscience Center, University of Helsinki, Finland (d) SUNREGEN HEALTHCARE AG, Reinach, Switzerland

⇒ Article

#2021-243

Comparison of two experimental mouse dry eye models through inflammatory gene set enrichment analysis based on a multiplexed transcriptomic approach

KESSAL K (a),(b),(c), DAULL P (d), CIMBOLINI N (e), FERAILLE L (e), GRILLO S (e), DOCQUIER M (f), BAUDOUIN C (a),(b),(c),(g), BRIGNOLE-BAUDOUIN F (a),(b),(c),(h), GARRIGUE JS (d)

Int. J. Mol. Sci. 2021; 22, 10770. doi: 10.3390/ijms221910770

(a) INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU ForeSight, Sorbonne Université UM80, Paris, France - (b) Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, INSERM-DGOS CIC1423, IHU FOReSight, Paris, France - (c) Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France - (d) SANTEN SAS, Evry, France - (e)  IRIS PHARMA, La Gaude, France - (f) iGE3 Genomics Platform, University of Geneva, Geneva, Switzerland - (g) Ambroise Paré, APHP, Department of Ophthalmology, University Paris Saclay, Boulogne, France - (h) Faculté de Pharmacie, Université de Paris, Paris, France

⇒ Article

#2021-240

Assessment of a new nanostructured microemulsion system for ocular delivery of Sorafenib to posterior segment of the eye

SANTONOCITO M (a), ZAPPULLA C (a),  VIOLA S (a), LA ROSA LR (a), SOLFATO E (a), ABBATE I (a), TARALLO V (b), APICELLA I (b), PLATANIA CBM (c), MAUGERI G (c), D’AGATA V (c), BUCOLO C (c), DE FALCO S (b), MAZZONE MG (a), GIULIANO F (a)

Int. J. Mol. Sci. 2021; 22, 4404. doi: 10.3390/ijms22094404 (collaboration)

(a) SIFI S.p.A., Catania, Italy - (b) Institute of Genetics and Biophysics, CNR, Napoli, Italy - (c) Department of Biomedical and Biotechnological Sciences, University of Catania, Italy

⇒ Article

#2021-239

Review of preclinical outcomes of a topical cationic emulsion of cyclosporine A for the treatment of ocular surface diseases

DAULL P (a), BAUDOUIN C (b), LIANG H (c), FERAILLE L (d), BARABINO S (e), GARRIGUE JS (a)

Ocul. Immunol. Inflamm. 2021; 1-11. doi: 10.1080/09273948.2021.1957124

(a) SANTEN SAS, Evry, France  - (b) CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France - (c) Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France - (d) IRIS PHARMA, La Gaude, France - (e) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy

⇒ Article

#2021-238

MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment

ENTCHEV E (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), JANTZEN I (a),  ROUSSEY A (a),  GERMAIN JM (a), ZHANG H (c), LUCCARRINI JM (a), LACOMBE O (a), YOUNG S (c)(d), FERAILLE L (b), TALLANDIER M (a)

Mol. Genet. Metab. 2021. doi: 10.1016/j.ymgme.2021.07.008

(a) INVENTIVA PHARMA, Daix, France, (b) IRIS PHARMA, La Gaude, France, (c) DUKE UNIVERSITY HEALTH SYSTEM BIOCHEMICAL GENETICS LAB, Durham, NC, USA, (d) DUKE SCHOOL OF MEDICINE, Durham, NC, USA

⇒ Article

#2021-236

Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye

DAULL P (a), NAGANO T (b), GROS E (c), FERAILLE L (c), BARABINO S (d), GARRIGUE JS (a)

Curr. Eye Res. 2021. doi: 10.1080/02713683.2021.1878228

(a) SANTEN SAS, Evry, France  - (b) SANTEN Pharmaceutical Co., Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France - (d) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy

⇒ Article

#2021-235

DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously

BECKMANN R (a), JENSEN K (a), FENN S (a) et al.

Nature 2021; 12, 708. doi: 10.1038/s41467-021-20949-3 (collaboration)

(a) ROCHE PHARMA Research and Early Development, Penzberg, Germany

⇒ Article

#2020-231

Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB–VCAM-1 axis

Y LI (a), A ALHENDI (a), MC YEH (a), M ELAHY (a), F SANTIAGO (a), N DESHPANDE (b), B WU (a), E CHAN (a), S INAM (a), L PRADO-LOURENCO (a), J MARCHAND (c), R JOYCE (c), L WILKINSON-WHITE (d), M RAFTERY (e), M ZHU (f), (g), (h), S ADAMSON (h), F BARNAT (i), K VIAUD-QUENTRIC (i), J SOCKLER (j), J MACKAY (k), A CHANG (g), (h), (l), P MITCHELL (m), S MARCUCCIO (c), (n), L KHACHIGIAN (a)

Sci. Adv. 2020; 6 : eaaz7815. doi: 10.1126/sciadv.aaz7815

(a) Vascular Biology and Translational Research, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia (b) Systems Biology Initiative, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (c) ADVANCED MOLECULAR TECHNOLOGIES Pty Ltd, Scoresby, Australia – (d) Sydney Analytical Core Facility, UNIVERSITY OF SYDNEY, Australia – (e) Bioanalytical Mass Spectrometry Facility, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (f) New South Wales Tissue Bank, Kogarah, Australia – (g) SAVE SIGHT INSTITUTE, University of Sydney, Australia – (h) GREENLIGHT CLINICAL Pty. Ltd., Woolloomooloo, Australia – (i) IRIS PHARMA, La Gaude, France – (j) DATAPHARM AUSTRALIA Pty. Ltd., Drummoyne, Australia – (k) School of Life and Environmental Sciences, UNIVERSITY OF SYDNEY, Australia – (l) Sydney Eye Hospital, Australia – (m) Centre for Vision Research, WESTMEAD INSTITUTE OF MEDICAL RESEARCH, Westmead, Australia – (n) La Trobe Institute for Molecular Science, Melbourne, Australia.

⇒ Article

#2020-230

SBC003 demonstrates neuroprotective effects in a murine model of N-nitroso-N-methylurea (NMU) induced photoreceptor degeneration

DONG Y (a), HARKIN K (b), FERAILLE L (c), CHEN M (b), XU H (b)

Invest. Ophthalmol. Vis. Sci. 2020;61(7):2475. 

(a) SUNREGEN HEALTHCARE AG, Allschwil, Switzerland - (b) QUEEN'S UNIVERSITY BELFAST, United Kingdom - (c) IRIS PHARMA, La Gaude, France

⇒ Abstract

#2020-229

The uni-nephrectomized and salt-loaded SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy

SHINOHARA M (a), BRIAND F (b), ANTONELLI S (c), MAURO V (c), CIMBOLINI N (c), BROUSSEAU E (b), OHTA T (d), MIYAJIMA K (e), KAGEYAMA Y (a), FERAILLE L (c), SULPICE T (b)

Japanese Society of Toxicologic Pathology meeting 2020; Tokuo, JAPAN

(a) CLEA Japan Inc., Tokyo, Japan - (b) PHYSIOGENEX, Labege, France - (c) IRIS PHARMA, La Gaude, France - (d) Kyoto University, Kyoto, Japan - (e) Tokyo University of Agriculture, Tokyo, Japan

#2019-247

The potential effect of human chorionic gonadotropin on vasoproliferative disorders of the immature retina

MOVSAS TZ (a), MUTHUSAMY A (b) (collaboration)

Neuroreport. 2018; 29:18, 1525-1529. doi: 10.1097/WNR.0000000000001140 (collaboration)

(a) ZIETCHICK RESEARCH INSTITUTE, Plymouth, MI, USA - (b)  Michigan State University, East Lansing, MI, USA

⇒ Article

#2019-222

Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops

DAULL P (a), BARABINO S (b), FERAILLE L (c), KESSAL K (d), DOCQUIER (e), PARSADANIANTZ S (d), BAUDOUIN C (d,f), GARRIGUE JS (a)

Curr. Eye Res. 2019 Jan 21:1-10. doi: 10.1080/02713683.2018.1563197

(a)SANTEN SAS, Evry, France - (b) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy - (c) IRIS PHARMA, La Gaude, France - (d) INSTITUT DE LA VISION, Paris, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) Quinze-Vingts National Ophthalmology Hospital, Paris, France 

⇒ Article  ⇒ Abstract

#2019-221

Chronic model of uveitis in rabbit - Efficacy of Triamcinolone Acetonide

QUENTRIC Y (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), FERAILLE L (a), ELENA PP (a)

ARVO meeting 2019; Vancouver - CANADA. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):800.

(a) IRIS PHARMA, La Gaude, France

⇒ Poster  ⇒ Abstract

#2019-220

Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye

DAULL P (a) , NAGANO T (b), OKADA S (b), GROS E (c), FERAILLE L (c), GARRIGUE JS (a)

ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):292.

(a) SANTEN SAS, Evry, France  - (b) SANTEN Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France

⇒ Poster  ⇒ Abstract

#2019-219

Dry Eye: Efficacy evaluation of two synthetic peptides from Chondrocyte Derived ExtraCellular Matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye

BAIK T (a), CHOI J (a), MIN K (a), FERAILLE L (b), RAYMOND E (b), ELENA PP (b)

ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):291.

(a) YUYU PHARMA, Seoul, The Republic of Korea - (b) IRIS PHARMA, La Gaude, France

⇒ Abstract

#2019-218

Comparison of inflammatory gene networks in dry eye between human and mouse

KESSAL K (a,b), DAULL P (c), FERAILLE L (d), CIMBOLINI N (d), LIANG H (a,b), DOCQUIER (e), BARABINO S (f), MELIK PARSADANIANTZ S (a), GARRIGUE JS (c), BAUDOUIN C (a,b), BAUDOUIN F (a,b)

ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):274.

(a) INSTITUT DE LA VISION, Paris, France - (b) Quinze-Vingts National Ophthalmology Hospital, Paris, France - (c) SANTEN SAS, Evry, France - (d) IRIS PHARMA, La Gaude, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) CLINICA OCULISTICA, Genova, Italy

⇒ Poster ⇒ Abstract

#2018-241

Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits

DAHMANA N (a), MUGNIER T (b),  GABRIEL D (b), KALTSATOS V (c), BERTAIM T (c),  BEHAR-COHEN F (d,e), GURNY R (a,b), KALIA Y (a) (collaboration)

Mol Pharm. 2018 Mar 5; 15(3):1192-1202. doi: 10.1021/acs.molpharmaceut.7b01028

(a) University of Geneva & University of Lausanne , Geneva, Switzerland – (b) APIDEL SA, Geneva, Switzerland – (c) CEVA Santé Animal , Libourne , France – (d) Fondation Asile des Aveugles , Hôpital Ophtalmique Jules-Gonin , Lausanne , Switzerland – (e) INSERM, UMRS 872 Team 17, Paris, France

⇒ Abstract

#2018-215

Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas

DAULL P (a), RAYMOND E (b), FERAILLE L (b), GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2018; doi: 10.1089/jop.2018.0040

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

⇒ Article

#2018-214

The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks

BRIAND F (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), SHINOHARA M (c), BROUSSEAU E (a), OHTA T (d), KAGEYAMA Y (c), FERAILLE L (b), SULPICE T (a)

ARVO meeting 2018; Hawaii - USA. Invest. Ophthalmol. Vis. Sci. 2018; 59(9):3573.

(a) PHYSIOGENEX, Labege, France - (b) IRIS PHARMA, La Gaude, France - (c) CLEA Japan Inc., Tokyo, Japan - (d) JAPAN TOBACCO Inc., Osaka, Japan

⇒ Poster     ⇒ Abstract

#2017-210

Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye

GARRIGUE JS (a), CIMBOLINI N (b), KESSAL K (c),  GROS E (b), MAURO V (b), BARABINO S (d), BAUDOUIN C (c), DAULL P (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 800.

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy

⇒ Abstract

#2017-209

Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration

ELENA PP (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), LAMONERIE T (b), FERAILLE L (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):4532.

(a) IRIS PHARMA, La Gaude, France - (b) UNIVERSITE DE NICE, Nice, France

⇒ Abstract

#2017-208

Corneal transcriptome changes in a mouse model of dry eye

DAULL P (a), FERAILLE L (b), KESSAL K (c),  ELENA PP (b), BARABINO S (d), BAUDOUIN C (c), GARRIGUE JS (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 797.

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy

⇒ Abstract

#2016-223

Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye

QUENTRIC Y (a), DAULL P (b), FERAILLE L (a), ELENA PP (a), GARRIGUE JS (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 422.

(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France

⇒ Poster

#2016-205

Norbixin Protects Retinal Pigmented Epithelium Cells and Photoreceptors against A2E-Mediated Phototoxicity In Vitro and In Vivo

FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France

⇒ Article

#2016-204

Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye

DAULL P (a), FERAILLE L (b), BARABINO S (c), CIMBOLINI N (b), GRILLO-ANTONELLI S (b), MAURO V (b), GARRIGUE JS (a)

Exp. Eye Res. 2016; 153:159-164 

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy

⇒ Article

#2016-201

SMA+ perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model

ELENA PP (a), MAURO V (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), VIAUD-QUENTRIC K (a), FERAILLE L (a)

EVER meeting 2016; Nice - France.

(a) IRIS PHARMA, La Gaude, France

⇒ Poster   ⇒ Abstract

#2016-200

Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems

ELENA PP (a)

Ocular Drug Delivery; Berlin - Germany. Oral communication

(a) IRIS PHARMA, La Gaude, France

#2016-199

Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye

GARRIGUE JS (a), DAULL P (a), FERAILLE L (b), BARABINO S (c)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12): 421.

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy

⇒ Poster

#2016-198

BIO201: a new drug candidate for the treatment of dry AMD

FONTAINE V (a), BRAZHNIKOVA E (a), MONTEIRO E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 1119.

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France

⇒ Poster

#2016-196

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2016; doi: 10.1089/jop.2015.0054

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

⇒ Article

#2015-216

HL036337 Ophthalmic Solution: Topical TNF Blocker for Dry Eye Disease

Protein and AntiboPEGS meeting 2015 Boston, MA (collaboration)

HanAll BioPharma Co., Ltd, Seoul, Korea

#2015-195

Cationic emulsion of cyclosporine for the management of ocular surface inflammation: a preclinical evaluation

DAULL P (a), FERAILLE L (b), AMRANE M (a), ELENA PP (b), GARRIGUE JS (a)

IOIS meeting 2015; San Francisco – USA

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

⇒ Poster

#2015-194

Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing

DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a)

EVER meeting 2015; Nice – France. Poster T034; doi: 10.1111/j.1755-3768.2015.0448

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

⇒ Abstract

#2015-193

Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye

CIMBOLINI N (a), GRILLO-ANTONELLI S (a), MAURO V (a), FERAILLE L (a), ELENA PP (a)

EVER meeting 2015; Nice – France. Poster T031; doi: 10.1111/j.1755-3768.2015.0420

(a) IRIS PHARMA, La Gaude, France

⇒ Poster

#2015-192

Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye

DAULL P (a), FERAILLE L (b), BARABINO S (c), GARRIGUE JS (a)

ARVO meeting 2015; Denver, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56: 4468.

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy

⇒ Poster ⇒ Abstract

#2015-191

Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization

KLAR J (d), BOETTGER M (a,d), FREUNDLIEB J (c), KELDENICH J (c), ELENA PP (b), VON DEGENFELD G (d)

ARVO meeting 2015; DENVER, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56(7): 426.92.

(a) Clinical Sciences Experimental Medicine, BAYER PHARMA AG, Wuppertal, Germany - (b) IRIS PHARMA, Nice, France - (c) BAYER PHARMA AG, Wuppertal, Germany - (d) Ophthalmology, BAYER PHARMA AG, Wuppertal, Germany

⇒ Abstract

#2015-190

Comparison of the effect of Dexamethasone and Prednisolone Acetate in a rat model of glucocorticoid-induced ocular hypertension following topical delivery

ELENA PP (a), CIMBOLINI N (a), GRILLO-ANTONELLI S (a), BOUZIN M (a), FERAILLE L (a), VIAUD-QUENTRIC K (a), NICOLAS MF (b), LAURENT S (c), BLOT C (c)

ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 2001 - Poster D0244

(a) IRIS PHARMA, Nice, France - (b) SANOFI R&D - LGCR, Vitry-sur-Seine, France - (c) SANOFI R&D - Ophthalmology Unit, Paris, France

⇒ Abstract

#2014-224

Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation

Invest. Ophthalmol. Vis. Sci 2014; 55: 2859. (collaboration)

TO-BBB TECHNOLOGIES BV, Leiden, Netherlands

⇒ Article

#2014-188

The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye

BARABINO S (a), GRILLO-ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b), BOUZIN M (b)

Invest. Ophthalmol. Vis. Sci. 2014; 55: 6499-6504 doi:10.1167/iovs.14-14548

(a) CLINICA OCULISTICA, Genoa, Italy - (b) IRIS PHARMA, Nice, France

⇒ Article

#2014-187

Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma

GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), ELENA PP (a)

EVER meeting 2014; Nice – France. Poster T017

(a) IRIS PHARMA, Nice, France

⇒ Poster   ⇒ Abstract

#2013-181

Dry eye: two experimental rodent models for drug development

CIMBOLINI N (a), ANTONELLI S (a), BARABINO S (b), FERAILLE L (a), MARGARON P (a), ELENA PP (a)

TFOS meeting 2013; Taormina - Sicily - Italy

(a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genoa, Italy

⇒ Poster

#2013-180

Effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a)

EVER meeting 2013; Nice – France. Poster S008

(a) IRIS PHARMA, Nice, France

⇒ Poster   ⇒ Abstract

#2013-179

Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N (a), GRILLO-ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a)

ISOPT meeting 2013; Paris – France

(a) IRIS PHARMA, Nice, France

⇒ Poster

#2013-176

Comparison of two rodent models of dry eye induced by Scopolamine

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), BARABINO S (b), MARGARON P (a)

ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065

(a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genoa, Italy

⇒ Abstract

#2012-173

Protection of blue light induced retinal degeneration by the free radical scavenger Phenyl-N-tert-butylnitrone and a serotonin receptor 5-HT1a agonist in rats

GRILLO-ANTONELLI S (a), CIMBOLINI N (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a)

EVER meeting 2012; Nice - France. Poster S063

(a) IRIS PHARMA, Nice, France

⇒ Poster   ⇒ Abstract

#2012-172

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P (a), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c), GARRIGUE JS (a)

EVER meeting 2012; Nice - France. Poster T036

(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

⇒ Poster ⇒ Abstract

#2012-171

Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping

DAULL P (a), GARRIGUE JS (a), FERAILLE L (b), BAUDOUIN C (c), ELENA PP (b)

EVER meeting 2012; Nice - France. Poster T037

(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

⇒ Poster ⇒ Abstract

#2012-170

Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats

ELENA PP (a), VIAUD-QUENTRIC K (a), CHARFEDDINE R (b), REKIK R (b)

EVER meeting 2012; Nice - France. Poster F029

(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

⇒ Abstract

#2012-168

Anti-inflammatory Effects Of Glucocorticoids On Endotoxin-induced Uveitis (EIU) In Rats: Impact Of The Mode Of Administration

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D1145

(a) IRIS PHARMA, Nice, France

⇒ Poster

#2012-167

Assessment of Intra-Ocular Pressure lowering effect of novel gel formulations of Latanoprost and Timolol in nonhuman primates following topical delivery

GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), BERMON F (b), MARGARON P (b), POLZER H (c), LAWRENCE MS (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D812

(a) RXGEN, Hamden, CT, USA - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany

⇒ Abstract

#2010-160

Ocular Distribution and Spectrum of Activity of a Fully Human Anti-Herpes Simplex Virus IgG Fab Fragment, Following Topical Application

BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), ELENA PP (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), COMBETTE JM (d)

ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991 - Poster D1028

(a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI, USA - (d) RIBOVAX BIOTECHNOLOGIES, Petit-Lancy, Switzerland - (e) CALMUNE CORPORATION, San Diego, CA, USA - (f) IRIS PHARMA, Nice, France - (g) Hotel-Dieu University Hospital, Paris, France

⇒ Abstract

#2009-154

Corneal Effect of Topical Diclofenac co-Administration with Aminoside and Steroid in Rabbits

CAILLAUD T (a), VIAUD K (a), ELENA PP (a)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957

(a) IRIS PHARMA, Nice, France

⇒ Poster

#2008-149

Immunohistochemistry and in situ Zymography to Assess Matrix Metalloproteinases Expression and Activation by Latanoprost in Rat Uveoscleral Pathway

ELENA PP (a), FRETON A (a), SPADAFORA A (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), LAZDUNSKI M (b)

ARVO meeting 2008; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2008; 49: 2616.

(a) IRIS PHARMA, Nice, France - (b) IPMC-UMR 6097, Valbonne, France

⇒ Abstract

#2007-148

Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC)

LAMBERT G (a), RABINOVICH-GUILATT L (a)

ARVO meeting 2007; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2007; 48: 2301. (collaboration)

(a) NOVAGALI PHARMA SA, Evry, France

⇒ Abstract

#2007-141

In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation

JENSEN L (a), HJARNAA P (a), FENSHOLDT J (a), ELENA PP (b), ABELL K (a), PETERSEN TK (a)

8th World Congress on Inflammation 2007; Copenhagen, Denmark. Inflamm Res. 2007; 56(suppl.3): S443, abstract P07.21

(a) LEO PHARMA, Ballerup, Denmark - (b) IRIS PHARMA, Nice, France 

⇒ Abstract

#2007-225

Ether-Lipid-Deficient-Mice Display Pigmentary Glaucoma Features as Well as Abnormal Retinal Vasculature

ACAR N (a), SICARD P (b), SCHNEBELEN C (a), CIMBOLINI N (c), IVINGS L (a), GRILLO-ANTONELLI S (c), ROCHETTE L (b), CREUZOT-GARCHER CP (a,d), BRETILLON L (a), JUST WW (e)

(a) INRA, Dijon, France - (b) Faculties of Medicine and Pharmacy, Dijon, France - (c) IRIS PHARMA, Nice, France - (d) University Hospital, Dijon, France - (e) Biochemie Zentrum Heidelberg (BZH), Heidelberg, Germany

⇒ Abstract

#2006-128

Effects of Dexamethasone in a Rat model of choroidal neovascularization

FERAILLE L (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), CAILLAUD T (a), ELENA PP (a)

Ocular Anti-Angiogenesis meeting 2006; London - United Kingdom

(a) IRIS PHARMA, Nice, France

⇒ Poster

#2005-127

Variation of Krüppel-like factors levels in mouse corneal model of angiogenesis

CHIAMBARETTA F, DE GRAEVE F, FERAILLE L, NEZZAR H, MARCEAU G, DASTUGNE B, RIGAL D, ELENA PP, SAPIN V

ARVO meeting 2005; Fort Lauderdale, FL. Invest. Ophthalmol. Vis. Sci. 2005; 46: ARVO e-abstract No. 2609

#2005-123

Variation of krüppel-like factors ARNm levels in a mouse corneal model of angiogenesis

CHIAMBARETTA F, NEZZAR H, FERAILLE L, DE GRAEVE F, MARCEAU G, ELENA PP, RIGAL D, DASTUGUE B, SAPIN V

SFO meeting 2005; Paris – France. Abstract No. 380

#2004-116

PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hypoxic stimuli

ELENA PP (a), AMAR T (a), CAILLAUD T(a), WONG M (b), BIZEC JC (c)

ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053

(a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, East Hanover, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland

⇒ Abstract

#2004-115

PKC412 reduces retinal neovascularization induced by hypoxic stimuli in pup mice

CAILLAUD T (a), AMAR T (a), OTTLECZ A (b), WONG M (c), LAMBROU GN (b), ELENA PP (a)

ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4062

(a) IRIS PHARMA, Nice, France - (b) NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) NOVARTIS PHARMA, East Hanover, USA

⇒ Abstract

#2002-113

Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits

YERXA BR (a), DOUGLASS JG (a), ELENA PP (b), CAILLAUD T (b), AMAR T (b), REDICK CC (a), PETERSON WM (a)

Adv. Exp. Med. Biol. 2002; 506: 261-265

(a) Inspire Pharmaceuticals, Durham, USA - (b) IRIS PHARMA, Nice, France

 ⇒ Abstract

#2001-110

Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits

FLEISCHHAUER JC (a), LIU R (a), ELENA PP (b), FLAMMER J (a), HAEFLIGER IO (a)

Klin. Monatsbl. Augenheidkd. 2001; 218: 351-353

(a) Laboratory of Ocular Pharmacology and Physiology, Basel, Switzerland - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2001-108

Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery

ELENA PP, MCFARLANE S, GLOVER DR, AMAR T, CAILLAUD T

ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915

#2000-234

Effect of CO 2 pneumoperitoneum on early cellular markers of retinal ischemia in rabbits with a-chymotrypsin–induced glaucoma

LENTSCHENE C (a), FREDJ-REYGROBELLET D (b),  BOUAZIZ H (c),  MAZOIT JX (d),  NIESSEN F (a), BENHAMOU D (a)

Surg. Endosc. 2000; 14: 1057–1961; doi: 10.1007/s004640000257 (collaboration) 

(a) Hôpital Antoine Béclère, Clamart, France - (b) Faculté de Médecine Nice, France - (c) Hôpital Central, Nancy, France - (d) Hôpital de Bicêtre, le Kremlin Bicêtre Cedex, France

#2000-104

Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension

LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, ELENA PP, MAFFRAND J, LE FUR G

J. Ocul. Pharmacol. Ther. 2000; 16: 203-216

⇒ Abstract 

#2000-103

Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits

PISELLA PJ (a,b), FILLACIER K (d), ELENA PP (e), DEBBASCH C (b,c), BAUDOUIN C (a)

Ophthalmic Res. 2000; 32: 3-8

(a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France

⇒ Article

#2000-101

Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter

TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, ELENA PP, TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214

#2000-99

Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits

YERXA BR, DOUGLASS JG, ELENA PP, CAILLAUD T, AMAR T, PETERSON WM

(3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI - USA) Cornea 2000; 19: S138

#1999-97

Benefits of a vasopressin V2 receptor antagonist, SR 121463, in the treatment of ocular hypertension in the rabbit

SERRADEIL-LE GAL C, LACHERETZ F, BARBIER A, ELENA PP, PASCAL M, MAFFRAND JP, LE FUR G

World Congress on Neurohypophysial Hormones. 1999; Edinburgh - UK

#1999-96

INS365, a P2Y2 receptor agonist, increases Schirmer scores in albino rabbits

YERXA BR, ELENA PP, CAILLAUD T, AMAR T, EVANS R

ARVO meeting 1999; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1999; 40: S540, abstract No. 2848

#1998-95

Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy

BAUDOUIN C, KHOSRAVI E, PISELLA PJ, ETTAICHE M, ELENA PP

Ophthalmic Res. 1998; 30: 340-350

⇒ Abstract

#1998-94

The effect of pneumoperitoneum on intraocular pressure in rabbits with α-chymotrypsin-induced glaucoma

LENTSCHENER C, LEVEQUE JP, MAZOIT JX, BENHAMOU D

Anesth. Analg. 1998; 86: 1283-1288. (collaboration)

⇒ Article

#1998-93

Activity of SR121463, a selective non-peptide vasopressine V2 receptor antagonist, in a rabbit model of glaucoma

LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, ELENA PP, MAFFRAND JP, LE FUR G

(ISER 1998 Abstract No. 795; Paris - France) Exp. Eye Res. 1998; 67: S239

#1998-92

Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat

FREDJ-REYGROBELLET D, CAILLAUD T, ELENA PP

ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S993, abstract No. 4591

#1998-91

Comparison of efficacy between ketotifen and olopatadine eyedrops in allergic conjunctivitis

ELENA PP, AMAR T, FETZ A, SCHOCH C

ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S549, abstract No. 2531

#1997-90

Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits

ELENA PP, JAUCH A

J. Ocul. Pharmacol. Ther. 1997; 13: 551-558

⇒ Abstract

#1997-89

Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP, ELENA PP, VILAIN C

ISECOPP meeting 1997 Munich – Germany, p. 12

#1997-87

Analyse de l'inflammation et de la prolifération cellulaire intra-oculaires dans un modèle expérimental de prolifération vitréorétinienne

PISELLA PJ, BECQUET F, ELENA PP, BAUDOUIN C

Ophtalmologie (France) 1997; 11: 369-371

#1997-86

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits

TILLEUL P, DENIS P, MAIGNEN F, ELENA PP, NORDMANN JP, LEVERGE R, ROSTENE W

Ophthalmic Res. 1997; 29: 218-226

⇒ Abstract

#1997-85

Retinal damage and protection after ischemic injury in the rat: a reappraisal

ELENA PP, CAILLAUD T, AMAR T, HARITON C

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S888, abstract No. 4151

#1997-83

Rilmenidine: effect on intraocular pressure in alpha-chymotrypsin rabbits

AMAR T, NORDMANN JP, CASTAGNE I, VILAIN C, ELENA PP

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S814, abstract No. 3790

#1996-78

Histological and cytological retinal changes after pressure-induced ischemia in rat eye

FREDJ-REYGROBELLET D, TABIASCO J, BALAS D, DENIS P, and ELENA PP

(JERMOV 1996 Abstract No. 399; Montpellier - France) Vision Res. 1996; 36: S220

#1997-76

Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat

MOREL MANDRINO P, CAILLAUD T, ELENA PP, HARITON C

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S103, abstract No. 502

#1996-81

Inflammation measurement and immunocharacterization of cell proliferation in experimental PVR

BAUDOUIN C, PISELLA PJ, KHOSRAVI E, ETTAICHE M, ELENA PP

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S391, abstract No. 1808

#1996-77

Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis

ELENA PP, KHOSRAVI E, BORBE H, HERBST M, PETER G

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719

#1995-73

Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs

KHOSRAVI E, ELENA PP, HARITON C

Inflamm. Res. 1995; 44: 47-54

#1995-72

Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP, PERCICOT CL, ELENA PP, MATHIS GA

ISECOPP meeting 1995; Geneva – Switzerland, p. 35

#1995-65

Dimethindene maleate in allergic conjunctivitis: a new indication for an old drug

ELENA PP, KHOSRAVI E, HARITON C

ARVO meeting 1995; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S1014, abstract No. 4699

#1994-61

Topical sodium sucrose octasulphate reduces corneal lesions in a keratoconjunctivitis sicca model in the rat

CHIBRET H, ELENA PP, KHOSRAVI E, FREDJ-REYGROBELLET D

ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1693, abstract No. 2039

#1994-58

Angiotensin-II antagonists reduce intraocular pressure by a combined effect on aqueous humor synthesis and outflow

MATHIS GA, PERCICOT C, MERMOUD A, ELENA PP

ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35; 1483, abstract No. 1060

#1993-54

Mifepristone (RU 486): in vitro binding to glucocorticoid receptors in iris-ciliary body and in vivo effects on intraocular pressure in rabbits

DENIS P, ELENA PP, NORDMANN JP, SARRIEAU A, SARAUX H, ROSTENE W

ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 925, abstract No. 1115

#1986-11

Effects of a new anti-allergic agent: the magnesium salt of N-Acetyl-Aspartyl-Glutamic Acid on experimental allergic inflammation of the rabbit eye

LAPALUS P, MOULIN G, BAYER V, FREDJ-REYGROBELLET D, ELENA PP

Curr. Eye Res. 1986; 5: 517-522

#1986-9

Système alpha-adrenergique et pression intra-oculaire

LAPALUS P, ELENA PP

Rencontres Internationales de Chimie Thérapeutique, Clermont-Ferrand - France 1986

#2022-244

A comparative pharmacokinetics study of 3 Latanoprost eyedrops solutions containing various excipients in an animal model

REBIKA H (a),(c), CHAUCHAT L (a), AMAR T (b), VIAUD-QUENTRIC K (b), GUERIN C (a)

ARVO meeting 2022; Denver, CO - USA. Abstract No. 4166 – F0158

Invest. Ophthalmol. Vis. Sci. 2022; 63(7):4166 – F0158.

(a)  HORUS PHARMA, Saint Laurent du Var, France – (b) IRIS PHARMA, La Gaude, France – (c) Centre Hospitalier Universitaire de Clermont-Ferrand, France

⇒ Abstract

#2017-213

Exploratory ocular surface distribution studies of azithromycin formulations based on semifluorinated alkanes

FISCHER K (a), GRILLENBERGER R (a), AMAR T (b), KRÖSSER S (a)

EVER meeting 2017; Nice, France. Acta Ophthalmologica. doi: 10.1111/j.1755-3768.2017.0S029

(a) NOVALIQ GmbH, 69120 Heidelberg, Germany - (b)  IRIS PHARMA, La Gaude, France

⇒ Poster  ⇒ Abstract

#2017-212

Oral administration of the 11bhydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

SCHWAB D (a), STURM C (a), PORTRON A (a), FUERST-RECKTENWALD S (b), HAINZL D (c), JORDAN P (d), STEWART W (e), TEPEDINO M (f), DUBINER H (g)

BMJ Open Ophth 2017; 1:e000063. doi: 10.1136/bmjophth-2016-000063 (collaboration)

(a) ROCHE INNOVATION CENTER, Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (b)  ROCHE INNOVATION CENTER, Translational Medicine, Roche Pharmaceutical Research and Early Development,Basel, Switzerland - (c) ROCHE INNOVATION CENTER, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Basel, Switzerland (d) Department of Biometrics, Product development, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (e) PRN Pharmaceutical Research Network, LLC, Cheyenne, Wyoming, USA - (f) Cornerstone Eye Care, Division of Health Care, High Point, North Carolina, USA - (g) Eye Care Centers Management, Inc., Clayton Eye Center, Morrow, Georgia, USA

⇒ Article

#2017-206

Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies

FUCHS H (a), IGNEY F (a)

J. Ocul. Pharmacol. Ther. 2017; doi: 10.1089/jop.2016.0083 (collaboration)

(a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany

#2014-185

Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits

VAN DER HEIDEN H (a,b), AMAR T (c), LICHTENAUEUR W (a)

ARVO meeting 2014; Orlando, FL - USA. Invest. Ophthalmol. Vis. Sci. April 2014, Vol.55, 453. doi:

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, La Gaude, France

⇒ Abstract

#2014-184

Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits

QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a), REKIK R (b)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036

(a) IRIS PHARMA, La Gaude, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia

⇒ Abstract

#2010-160

Ocular distribution and spectrum of activity of a fully human anti-herpes simplex virus IgG fab fragment, following topical application

BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), ELENA PP (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), COMBETTE JM (d)

ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991 - Poster D1028

(a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI, USA - (d) RIBOVAX BIOTECHNOLOGIES, Petit-Lancy, Switzerland - (e) CALMUNE CORPORATION, San Diego, CA, USA - (f) IRIS PHARMA, La Gaude, France - (g) Hotel-Dieu University Hospital, Paris, France

⇒ Abstract

#2009-156

Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation

AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b), CREAN C (b)

J. Ocul. Pharmacol. Ther. 2009; 25: 433-439

(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE PHARMACEUTICALS, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA

⇒ Abstract

#2009-153

Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations

ELENA PP (a), POLLIN C (a), BERMON F (a), AMAR T (a), CAILLAUD T (a), POLZER H (b)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002

(a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany 

⇒ Abstract

#2008-152

Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits

AMAR T (a), CAILLAUD T (a), ELENA PP (a)

Curr Eye Res. 2008; 33: 149-158

(a) IRIS PHARMA, Nice, France 

⇒ Abstract

#2007-226

Netildex versus Tobradex^®: ocular pharmacokinetic/pharmacodynamic after a single dose and after one-day treatment in pigmented rabbits

CIVIALE C (a), BLANCO A (a), SUDANO-ROCCARO A (a), AMAR T (b), MAZZONE M (a)

Invest. Ophthalmol. Vis. Sci. 2007; 48(13):4272. doi:

(a) SIFI SPA, Lavinaio-Aci San Antonio, Italy - (b) IRIS PHARMA, Nice, France 

⇒ Abstract

#2006-131

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits

CAILLAUD T (a), ROY P (b), VIAUD K (a), ELENA PP (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

#2006-130

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate

ROY P (a), VIAUD K (b), CAILLAUD T (b), ELENA PP (b)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110

(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2004-116

PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hypoxic stimuli

ELENA PP (a), AMAR T (a), CAILLAUD T (a), WONG M (b), BIZEC JC (c)

ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053

(a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, East Hanover, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland

⇒ Abstract

#2002-111

Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit

TISSIE G (a), SEBASTIAN C (a), ELENA PP (b), DRIOT JY (a), TRINQUAND C (a)

J. Ocul. Pharmacol. Ther. 2002; 18: 65-73

(a) LABORATOIRE BAUSCH & LOMB/CHAUVIN, Montpellier, France - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2001-108

Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery

ELENA PP, MCFARLANE S, GLOVER DR, AMAR T, CAILLAUD T

ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915

#2000-102

Localisation of Venoruton in rat blood vessel after single oral administration

SALLIN D, ELENA PP, ZIJLSTRA J

14th World Congress ot the 'Union Internationale de Phlebologie' Roma - Italy 2000

#2000-100

Alginic acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits

SEBASTIAN C, TISSIE G, DRIOT JY, ELENA PP, TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215

#1997-90

Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits

ELENA PP, JAUCH A

J. Ocul. Pharmacol. Ther. 1997; 13: 551-558

⇒ Abstract

#1997-84

Ocular distribution of Rescula^® Eye-Drops in the pigmented rabbit after a single topical administration

CAILLAUD T, AMAR T, HARITON C, ELENA PP

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S815, abstract No. 3796

#1996-77

Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis

ELENA PP, KHOSRAVI E, BORBE H, HERBST M, PETER G

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719

#1996-74

Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, LUYCKX J

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383

#1995-69

Lomefloxacin distribution after a single instillation in the infected eye of pigmented rabbits

KHOSRAVI E, ELENA PP, JAUCH A

ISECOPP meeting 1995; Geneva - Switzerland, p. 67

#1995-69

Lomefloxacin distribution after a single instillation in the infected eye of pigmented rabbits

KHOSRAVI E, ELENA PP, JAUCH A

ISECOPP meeting 1995; Geneva - Switzerland, p. 67

#1995-248

Distribution of Salicylate in Pigmented Rabbit Ocular Tissues After Application of a Prodrug, Sodium Monomethyl Trisilanol Orthohydroxybenzoate: In Vivo and Ex Vivo Studies

CHANALET L, ETTAICHE M, BAUDOUIN C, LAPALUS P (collaboration)

J. Ocul. Pharmacol. Ther. 1995; 11:1, 83-94 doi: 10.1089/jop.1995.11.83

⇒ Abstract

#1994-60

Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits

ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J, KHOSRAVI E

ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984

#1993-55

Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium

CHIBRET H, ELENA PP, KHOSRAVI E

ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712

#1993-53

Piribédil: affinité pour les récepteurs dopaminergiques rétiniens et profil pharmacocinétique oculaire

LAPALUS P (a), DENIS P (b), DRICI M (a), FREDJ-REYGROBELLET D (a), ELENA PP (c)

J. Neur. 1993; 240 (Suppl 1): S17-S21

(a) School medicine, dep. pharmacology, Nice, France - (b) Hôpital Saint-Antoine, Paris, France - (c) IRIS PHARMA, Nice, France 

⇒ Abstract

#1992-52

Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil

LAPALUS P, DENIS P, DRICI M, FREDJ-REYGROBELLET D, ELENA PP

J. Neurol. 1992; 239 (Suppl 1): S17-S21

⇒ Abstract

#1992-51

Ocular pharmacokinetics of trimetazidine in the pigmented rat after a single oral administration

ELENA PP, KHOSRAVI E, LAPALUS P, JOULIN Y, HARPEY C

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S55, abstract No. 184

#1992-49

Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit

ELENA PP (a), KHOSRAVI E (a), LAPALUS P (b), ULRICH E (c)

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182

(a) IRIS PHARMA, Nice, France - (b) School medicine, dep. pharmacology, Nice, France - (c) CIBA VISION, Switzerland

#1992-48

Preclinical pharmacokinetics of the 14C-labelled aldose reductase inhibitor methosorbinil (E-0722)

ELENA PP, KUNZ PA, LAPALUS P

SOE meeting 1992; Brussels - Belgium. P. 188, abstract No. 737

#1990-37

Ocular pharmacokinetics of ganciclovir gel after a single administration

LAPALUS P, ETTAICHE M, LUYCKX J, ELENA PP

AER meeting 1990; Bad Honnef - Germany. P. 58, abstract No. 94

#1990-36

Hymecel pharmacokinetics after a single intracameral injection in phakic and aphakic eyes of pigmented rabbits

ELENA PP, LAPALUS P, FREDJ-REYGROBELLET D, ETTAICHE M, ULRICH E

AER meeting 1990; Bad Honnef - Germany. P. 25, abstract No. 6

#1990-32

Retinal dopaminergic receptors and distribution of piribedil

LAPALUS P, ELENA PP, FREDJ-REYGROBELLET D, DENIS P

ENS meeting 1990; Brighton - UK

#1989-29

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye

FREDJ-REYGROBELLET D, ELENA PP, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D, LAPALUS P

Curr. Eye Res. 1989; 8: 1141-1152

#1989-20

Pharmacokinetics of topically-administered aldose reductase inhibitor (E-0722) on pigmented rabbit eye

LAPALUS P, FREDJ-REYGROBELLET D, ELENA PP

AER meeting 1989; Montpellier - France. Doc. Ophthalmol. 1990; 76: 129-130, abstract No. 45

#1989-19

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialised and intact rabbit eye

FREDJ-REYGROBELLET D, ELENA PP, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D, LAPALUS P

AER meeting 1989; Montpellier - France, Doc. Ophthalmol. 1990; 76: 111, abstract No. 13

#1984-3

Etude cinétique d'un anti-allergique, le 14C-T86 en instillation chez le lapin albinos

LAPALUS P, MOULIN G, BAYER V, ELENA PP, NICOLAS C, LAPALUS F

J. Biophys. Med. Nucl. 1984; 8: 195-198

#1984-2

Etude cinétique d'un anti-allergique, le 14C-T86, en instillation chez le lapin albinos

LAPALUS P, MOULIN G, BAYER V, ELENA PP, NICOLAS C, LAPALUS F

Congrès de Médecine Nucléaire de Langue Francaise; Nice - France 1984

#2018-215

Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas

DAULL P (a), RAYMOND E (b), FERAILLE L (b), GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2018; doi: 10.1089/jop.2018.0040

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

⇒ Article

#2017-227

Ocular tolerance in rabbits after intracameral administration of a fixed combination of tropicamide, phenylephrine, and lidocaine with and without rinsing

NUIJTS R (a), MENCUCCI R (b), VIAUD-QUENTRIC K (c), ELENA PP (c), OLMIERE C (d), BEHNDIG A (e)

J. Cataract Refr. Surg. 2017; 43: 673-679. doi: 10.1016/j.jcrs.2017.03.025

(a) Maastricht Universitair Medisch Centrum, the Netherlands – (b) University of Florence, Italy – (c) IRIS PHARMA, La Gaude, France – (d)  LABORATOIRES THEA, Clermont-Ferrand, France – (e) Umeå University, SWEDEN

⇒ Article ⇒ Abstract

#2017-207

Safety evaluation of cationic emulsions following refractive surgery procedures

QUENTRIC Y (a), DAULL P (b), GROS E (a), ANTONELLI S (a), MAURO V (a), FERAILLE L (a), GARRIGUE JS (b)

ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 5297 - Poster B0250

(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France

⇒ Poster

#2016-202

Ocular tolerance in rabbits of intracameral administration of MYDRANE, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery

OLMIERE C (a), VIAUD K (b)

EVER meeting 2016; Nice - France.

(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) IRIS PHARMA, Nice, France 

⇒ Abstract

#2016-197

Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient

Tolérance à long terme d’un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate

VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)

J. Fr. Ophtalmol. 2016; 39: 156-163; doi: 10.1016/j.jfo.2015.09.011

(a) IRIS PHARMA, Nice, France 

⇒ Abstract

#2015-189

In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits

QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264

(a) IRIS PHARMA, Nice, France 

⇒ Poster   ⇒ Abstract

#2014-183

Safety and tolerability of drugs within the suprachoroidal space in albino rabbits

PATEL S (a), VERHOEVEN R (a), BURKE B (a), CACCIAMANI F (b), VIAUD-QUENTRIC K (b), EDELHAUSER H (c,a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 4886 - Poster C0082

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France - (c) EMORY UNIV EYE CENTER, Atlanta, GA, USA

⇒ Abstract

#2013-178

CLS suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), PATEL S (a)

American College of toxicology 2013 San Antonio, Texas - USA. Poster P505

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

#2013-177

Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), PATEL S (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), AMAR T (b), YERXA B (a)

ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2009-154

Corneal effect of topical diclofenac co-administration with aminoside and steroid in rabbits

CAILLAUD T (a), VIAUD K (a), ELENA PP (a)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957

(a) IRIS PHARMA, Nice, France

⇒ Poster

#2007-147

Ocular tolerability of iontophoresis

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), CALIAS P (a)

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800

(a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2006-129

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits

ELENA PP (a), ROY P (b), VIAUD K (a), CAILLAUD T (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

⇒ Abstract

#1995-66

Lack of cytotoxic effect of ganciclovir and acyclovir on rabbit corneal epithelial cells in vitro

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, BAUDOUIN C, LUYCKX J

JERMOV meeting 1995; Montpellier - France. Vision Res. 1995; 35: S173, abstract No. P125

#1990-38

Cytotoxicity studies in ophthalmology

LAPALUS P, ETTAICHE M, FREDJ-REYGROBELLET D, JAMBOU D, ELENA PP

Lens Eye Toxic Res. 1990; 7: 231-242

#2020-228

Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial

KALLAB M (a), SZEGEDI S (a), HOMMER N (a), STEGMANN H (a), KAYA S (b), WERKMEISTER RM (a), SCHMIDL D (a), SCHMETTERER L (a)(c)(d)(e), GARHÖFER G (a)

Adv. Ther. 2020; 37: 329–341 doi: 10.1007/s12325-019-01137-8 (collaboration)

(a) Medical University of Vienna, Vienna, Austria - (b) Department of Ophthalmology, Hietzing Hospital, Vienna, Austria - (c) Singapore Eye Research Institute, Singapore, Singapore - (d) Nanyang Technological University, Singapore, Singapore - (e) Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore

⇒ Article

#2018-217

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study

ECONOMOU M (a), KOLSTAD LAUKELAND H (b,c), GRABSKA-LIBEREK I (d), ROULAND JF (e)

Clinical Ophthalmol. 2018; 12: 2399–2407 (collaboration)

(a) St Erik’s Eye Hospital, Stockholm, Sweden - (b) University Hospital, Trondheim, Norway - (c) Norwegian University of Science and Technology, Trondheim, Norway - (d) Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland - (e) Claude Huriez Hospital, Lille, France

⇒ Article

#2010-159

Dry Eye Syndrome : the regulatory challenge. Clinical trial and regulatory challenges faced by Iris Pharma in the development of dry eye therapies

QUENTRIC Y (a)

TFOS Global Dry Eye Experts' meeting 2010; Florence - Italy. Oral Communication

(a) IRIS PHARMA, Nice, France

#2009-155

Associer les patients atteints de DMLA à la recherche, est-ce possible?

BENCHABOUNE M (a)

Vu et Entendu. 2009; 2: 4

(a) IRIS PHARMA, Nice, France

⇒ Article

#2008-151

Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers

CHIAMBARETTA F, GARRAFFO R, ELENA PP, POULIQUEN P, DELVAL L, RIGAL D, DUBRAY C, GOLDSCHMIDT P, TABBARA K, COCHEREAU I

Eur. J. Ophthalmol. 2008; 18(1): 13-20

⇒ Article ⇒ Abstract

#2007-144

Trend of prescription of silicon hydrogel lens by ophthalmologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b)

29th IEEE EMBS Annual International Conference 2007; Lyon - France

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

#2007-143

A new method for intra ocular pressure in vivo measurement: first clinical trials

DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R, PUECH P

29th IEEE EMBS Annual International Conference 2007; Lyon - France

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:5763-5766. doi:10.1109/IEMBS.2007.4353656

⇒ Article  ⇒ Abstract 

#2006-139

Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C, BRON AM

Acta Ophthalmologica Scandinavica. 2006; 84 Supplement 239: 135

#2006-138

Amélioration de la symptomatologie chez des patients atteints de sécheresse oculaire et traités oralement par des acides gras polyinsaturés. Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C, PASSEMARD M, VIAU S, JOFFRE C, LAFONTAINE PO, ELENA PP, POULIQUEN P, BAUDOUIN C, BRON AM

SFO meeting 2006; Paris - France (Oral communication No. 220)

#2006-137

Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles 0₂ OPTIX TORIC

DELFOUR-MALECAZE M (a), STEVE L (b), CLIROPHTHA (c)

Réflexions Ophtalmol. 2006; 95: 50-53
(a) Toulouse, France (b) CIBA VISION France, Paris, France - (c) CLIROPHTHA, Nice, France

#2006-136

Improvement of dry eye symptoms with polyunsaturated fatty acids

CREUZOT C, PASSEMARD M, VIAU S, JOFFRE C, POULIQUEN P, ELENA PP, BRON A, BRIGNOLE F

J. Fr. Ophtalmol. 2006; 29(8): 868-73

⇒ Article

#2006-135

Trend of prescription of silicone hydrogel lens by ophthalmologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b)

36th ECLSO Congress 2006; Dubrovnik - Czech Republic. Abstract No. 9

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

#2006-134

Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT)

MONTARD M

Safir meeting 2006. Paris - France (collaboration)

#2006-133

Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C (a), PASSEMARD M (a), LAFONTAINE PO (a), VIAU S (b), JOFFRE C (b), ELENA PP (c), POULIQUEN P (d), BAUDOUIN C (e), BRON AM (a)

EVER meeting 2006; Vilamoura - Portugal. Free paper No. 3155 and poster No. 335

(a) Hopital General, Dijon, France - (b) INRA - Eye and Nutrition Unit, Dijon, France (c) CLIROPHTHA, Nice, France (d) LABORATOIRES THEA, Clermont-Ferrand, France - (e) CHNO XV-XX, Paris, France

⇒ Abstract

#2006-132

Improvement of dry eye symptoms with polyunsaturated fatty acids

GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C, BRON AM

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 236

⇒ Abstract

#2005-126

Regard^® : une enquête sur la tolérance et le confort oculaire d'une solution d'entretien pour lentilles de contact sans conservateur

MALET F, CLIROPHTHA

Réflexions Ophtalmol. 2005; 84: 62-65

#2005-125

Une nouvelle méthode de mesure de la pression intraoculaire

DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c), ELENA PP (d)

IRBM 26; 4: 285-290

(a) Institut de technologie médicale, CHRU, Lille, France - (b) Laboratoire de spectroscopie hertzienne, USTL, Villeneuve d’Ascq, France - (c) Hôpital Huriez, Lille, France - (d) IRIS PHARMA, Nice, France

⇒ Abstract

#2005-124

Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients

RENARD P (a), KOVALSKI JL (b), COCHEREAU I (c), JAULERRY S (d), WILLIAMSON W (e), ELENA PP (f), LABLACHE COMBIER M (g), ALLAIRE C (g), SIOU-MERMET R (g)

Graefe's Arch. Clin. and Exp. Ophthalmol. 2005; 243: 1221-1227

(a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) IRIS PHARMA-CLIROPHTHA, Nice, France - (g) BAUSCH & LOMB, Paris, France

⇒ Abstract

#2004-203

Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers

MAHE I (a), MOULY S (a), JARRIN I (a), OTERO J (a), TAVERA C (b), SIMONEAU G (c), TILLET Y (c), CONTI R (b), EL MESKI S (b), GAUDRIC A (a), JF BERGMANN (a)

Br. J. Clin. Pharmacol. 2004; 59:2 220 – 226 (collaboration)

(a) Hôpital Lariboisière, Paris, France - (b) IOLTECH, La Rochelle, France - (c) WHITE-TILLET Consultants, Chelles, France

⇒ Article

#2004-122

Ocular hypotensive effect of a new “once-daily” eye-dops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol^® 0.5% administered twice-daily

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c), FERREIRA VD (c)

ISOPT meeting 2004; Monte-Carlo – Monaco

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

#2004-121

Intérêt d’une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire

CHIAMBARETTA F (a), CREUZOT-GARCHER C (b), PILON F (a), POULIQUEN P (c), REBIKA H (c), DUBRAY C (d), RIGAL D (a)

J. Fr. Ophtalmol. 2004; 27, 7, 739-744 (collaboration)

(a) Hôpital Gabriel Montpied, Clermont-Ferrand, France - (b) CHU de Dijon, Dijon, France - (C) LABORATOIRES THEA, Clermont-Ferrand, France - (d) Unité de Pharmacologie Clinique, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France

⇒ Article

#2004-120

Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost

BRON A, VELASQUE L, REBICA H, POULIQUEN P, ELENA PP, ROULAND JF

J. Fr. Ophtalmol. 2004; 27(9 Pt 1): 971-7

⇒ Abstract

#2004-119

Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol^®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients

ROULAND JF (a), MOREL-MANDRINO P (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c)

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45(13): 2080. doi:

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

⇒ Abstract

#2004-118

Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients

ALLAIRE CM (a) , RENARD P (b) , KOVALSKI J (c) , COCHEREAU I (d) , JAULERRY S (e) , WILLIAMSON W (f) , ELENA PP (g), LABLACHE-COMBIER M (a)

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 957

(a) BAUSCH & LOMB, Paris, France - (b) Institut Vernes, Paris, France - (c) HIA Clermont Tonnerre, Brest, France - (d) CHRU, Angers, France - (e) CH Tarbes Vic Bigorre, Tarbes, France - (f) CH François Mitterrand, Pau, France - (g) IRIS PHARMA-CLIROPHTHA, Nice, France

⇒ Abstract

#2004-117

Efficacy and safety of diclofenac 0.1% ABAK^® versus preserved diclofenac^® 0.1% eye drops in controlling post-cataract surgery inflammation

GOLDSCHMIDT P, ELENA PP, BALDWIN H, DELVAL L, COLIN J

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 294

⇒ Abstract

#2002-112

Timolol 0.1% Gel (Nyogel 0.1%^®) Once Daily versus Conventional Timolol 0.5% Solution Twice Daily: A Comparison of Efficacy and Safety

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c), SUNDER RAJ P (d)

Ophthalmologica 2002; 216: 449-454

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany - (d) NOVARTIS OPHTHALMICS, Farnborough, UK

⇒ Abstract

#2001-109

A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c)

IGS meeting 2001; Prague - Czech Republic

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany

#2000-106

A new long acting ophthalmic formulation of carteolol containing alginic acid

SECHOY O (a), TISSIE G (a), SEBASTIAN C (a), MAURIN F (a), DRIOT JY (a), TRINQUANT C (a)

Int. J. Pharm. 2000; 207: 109-116 (collaboration)

(a) LABORATOIRE CHAUVIN, Montpellier, France

⇒ Abstract

#2000-105

Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducting the IOP of glaucomatous patients

ELENA PP, ROULAND JF, MOREL-MANDRINO P, POLZER H

ARVO meeting 2000; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2000; 41: S281, abstract No. 2477

#1998-233

Klinische und pharmakokinetische Untersuchungen zur perioperativen antiphlogistischen Wirksamkeit von Prednisolon-Gel bei der Kataraktextraktion

STRUKE HG, STOLDT G

Ohrloff C., Kohnen T., Duncker G. (eds) 11. Kongreß der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation und refraktive Chirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71952-3_60 (collaboration)

#1997-89

Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP, ELENA PP, VILAIN C

ISECOPP meeting 1997 Munich – Germany, p. 12

#1997-88

Efficacy and local ocular tolerance of Rescula eye drops in glaucoma patients

NORDMANN JP, ROULAND JF, ELENA PP, KAPOK B

ISECOPP meeting 1997 Munich – Germany, p. 27

#1997-82

Rilmenidine: safety and efficacy on intraocular pressure in healthy volunteers and glaucoma patients

NORDMANN JP, ELENA PP, MOREL-MANDRINO P, CASTAGNE I, VILAIN C

ARVO meeting 1997; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1997;38 : S559, abstract No. 2600

#1996-75

Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan^®) in healthy volunteers

POULIQUEN P (a), ELENA PP (b), MALECAZE F (c), LUYCKX J (a), LANOUE A (a), GOLDSCHMIDT P (d)

ARVO meeting 1996; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S313, abstract No. 1431

(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) CLIROPHTHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France

#1995-72

Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP, PERCICOT CL, ELENA PP, MATHIS GA

ISECOPP meeting 1995; Geneva – Switzerland, p. 35

#1995-71

One drop study to evaluate safety and efficacy of SR43845, a renin inhibitor, in healthy volunteers

DENIS P, NORDMANN JP, ELENA PP, JAILLON P, MATHIS G, SARAUX H

ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S734, abstract No. 3388

#1995-70

Evaluation of safety and efficacy of CGP38560, a renin inhibitor, in healthy volunteers and glaucoma subjects

NORDMANN JP, DENIS P, ELENA PP, MATHIS GA, SCHNARR KD, TETZLOFF W, KERKMANN T

ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S719, abstract No. 3317

#1994-59

Central nervous system control of intraocular pressure

DENIS P (a), NORDMANN JP (a), ELENA PP (b), SARAUX H (a), LAPALUS P (c)

Fundam. Clin. Pharmacol. (France) 1994; 8 : 230-237

(a) Hôpital Saint-Antoine, dep. ophthalmology, Paris, France - (b) IRIS PHARMA, Nice, France - (c) School medicine, dep. pharmacology,
Nice, France

#2014-182

Biocompatibility of MedinGel biodegradable drug delivery system in the eye

SPIS M (a), FERAILLE L (b), ANTONELLI S (b), CIMBOLINI N (b), ELENA PP (b), GAUDRIAULT G (a), PETIT A (a)

Invest. Ophthalmol. Vis. Sci. 2014;55(13):5273.

(a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2014-185

Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits

VAN DER HEIDEN H (a,b), AMAR T (c), LICHTENAUEUR W (a)

Invest. Ophthalmol. Vis. Sci. 2014; 014;55(13):453.

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France

⇒ Abstract

#2012-174

Assessment of a new device for conjunctival impression

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c)

MCLOSA meeting 2012; London - England

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France

#2012-166

Assessment of a new device for conjunctival impression

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c)

Invest. Ophthalmol. Vis. Sci. 2012;53(14):1868.

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France

⇒ Abstract

#2011-165

Assessment of a new device for conjunctival impression

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b)

Oral presentation. ISOPT meeting 2011; Vienna, Austria

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France

#2011-164

Explorations et imagerie rétinienne

BENCHABOUNE M (a)

STO meeting 2011; Tunis - Tunisia (Oral Communication in French)

(a) IRIS PHARMA, Nice, France

#2011-163

Adaptative optics imaging in age-related macular degeneration

GOCHO-NAKASHIMA K (a), BENCHABOUNE M (b), ULLERN M (a), LAMORY B (c), CHATEAU N (c), SAHEL JA (a), PAQUES M (a)

EVER meeting 2011; Crete - Greece (Oral Communication)

(a) INSERM 503, Paris, France - (b) IRIS PHARMA, Nice, France - (c) IMAGINE EYES, Orsay, France

⇒ Abstract

#2011-162

In vivo microscopic imaging of drusen using adaptive optics

LAMORY B (a), NAKASHIMA K (b), BENCHABOUNE M (b,c), ULLERN M (b), VUAILLAT E (a), SAHEL JA (b), PAQUES M (b)

ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 4469/A218

(a) IMAGINE EYES, Orsay, France - (b) INSERM 503, Paris, France - (c) IRIS PHARMA, Nice, France

⇒ Abstract

#2011-161

Evaluation of membrane material for impression cytology

ROY P (a), CIMBOLINI N (b), FERAILLE L (b), KECHAD M (b), ELENA PP (b)

ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1937 - Poster D918

(a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2007-147

Ocular tolerability of iontophoresis

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), CALIAS P (a)

Invest. Ophthalmol. Vis. Sci. 2007;48(13):5800.

(a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2007-146

New evaluation techniques in ocular surface diseases : comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig

FERAILLE L (a)

Oral presentation. EVER meeting 2007; Portoroz, Slovenia

(a) IRIS PHARMA, Nice, France

#2007-145

Update on drug delivery systems used in the anterior part of the eye : review of the new drug delivery systems for the anterior chamber

ELENA PP (a)

Oral presentation. ESCRS meeting 2007; Stockholm, Sweden

(a) IRIS PHARMA, Nice, France

#2007-144

Trend of prescription of silicon hydrogel lens by ophthalomologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b)

29th IEEE EMBS Annual International Conference 2007; Lyon - France

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

#2007-143

A new method for intra ocular pressure in vivo measurement: first clinical trials

DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c), ELENA PP (d), LOPES R (a), PUECH P (a)

29th IEEE EMBS Annual International Conference 2007; Lyon - France doi: 10.1109/IEMBS.2007.4353656

(a) INSERM 703, Lille, France - (b) Laboratoire de Spectroscopie Hertzienne, Lille, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France - (d) IRIS PHARMA, Nice, France

⇒ Abstract

#2006-137

Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles 0₂ OPTIX TORIC

DELFOUR-MALECAZE M (a), STEVE L (b), CLIROPHTHA (c)

Réflexions Ophtalmol. 2006; 95: 50-53

(a) Toulouse, France (b) CIBA VISION France, Paris, France - (c) CLIROPHTHA, Nice, France

#2006-135

Trend of prescription of silicone hydrogel lens by ophthalmologists and lens assessment by patients

CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b)

36th ECLSO Congress 2006; Dubrovnik - Czech Republic. Abstract No. 9

(a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France

#2006-134

Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT)

MONTARD M

Safir meeting 2006. Paris - France (collaboration).

#2006-131

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits

CAILLAUD T (a), ROY P (b), VIAUD K (a), ELENA PP (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

#2006-130

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate

ROY P (a), VIAUD K (b), CAILLAUD T (b), ELENA PP (b)

Invest. Ophthalmol. Vis. Sci. 2006;47(13):5110 

(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2006-129

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits

ELENA PP (a), ROY P (b), VIAUD K (a), CAILLAUD T (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

#2005-125

Une nouvelle méthode de mesure de la pression intraoculaire

DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c), ELENA PP (d)

IRBM 26; 4: 285-290 - doi:10.1016/j.rbmret.2005.04.013

(a) Institut de technologie médicale, CHRU, Lille, France - (b) Laboratoire de spectroscopie hertzienne, USTL, Villeneuve d’Ascq, France - (c) Hôpital Huriez, Lille, France - (d) IRIS PHARMA, Nice, France

⇒ Abstract

#1995-68

Non-invasive measurement of ocular temperature by using infrared thermographic analysis in immune and non-immune allergy models

ELENA PP, KHOSRAVI E, HARITON C

ISECOPP meeting 1995 Geneva - Switzerland, p. 60

#1991-47

La radioautographie en ophtalmologie: méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ

DENIS P, ELENA PP, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H, ROSTENE W

"Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113

#1990-34

Localization and characterization of receptors in human and animal eyes by “ in vitro ” autoradiography

ELENA PP, DENIS P, FREDJ-REYGROBELLET D, ROSTENE W, LAPALUS P

ISER meeting 1990; Helsinki - Finland, p 228, abstract No. 803

#2022-245

New Preservative-Free Formulation for the Enhanced Ocular Bioavailability of Prostaglandin Analogues in Glaucoma

ALVISET G (a),(b),(c), CORVIS Y (b), HAMMAD K (d), LEMUT J (e),(f), MAURY M (f), MIGNET N (b), BOUDY V (b),(c)

Pharmaceutics 2022, 14, 453. doi: 10.3390/pharmaceutics14020453 (collaboration)

(a) UNITHER Développement Bordeaux, Le Haillan, France – (b) CNRS, INSERM, UTCBS, Paris, France - (c) Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France – (d) CNRS, CiTCoM, Paris, France – (e) CMC Expert, Montpellier, France – (f) UNITHER PHARMACEUTICALS, Paris, France

⇒ Article

#2021-239

Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases

DAULL P (a), BAUDOUIN C (b), LIANG H (c), FERAILLE L (d), BARABINO S (e), GARRIGUE JS (a)

Ocul. Immunol. Inflamm. 2021. Aug 4;1-11 doi: 10.1080/09273948.2021.1957124

(a) SANTEN SAS, Evry, France  - (b) CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France - (c) Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France - (d) IRIS PHARMA, La Gaude, France - (e) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy

⇒ Article

#2021-236

Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye

DAULL P (a), NAGANO T (b), GROS E (c), FERAILLE L (c), BARABINO S (d), GARRIGUE JS (a)

Curr. Eye Res. 2021 Jan 15. doi: 10.1080/02713683.2021.1878228

(a) SANTEN SAS, Evry, France  - (b) SANTEN Pharmaceutical Co., Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France - (d) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy

⇒ Article

#2017-206

Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies

FUCHS H (a), IGNEY F (a)

J. Ocul. Pharmacol. Ther. 2017; doi: 10.1089/jop.2016.0083 (collaboration)

(a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany

#2015-197

Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient

Tolérance à long terme d’un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate

VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)

J. Fr. Ophtalmol. 2015; doi: 10.1016/j.jfo.2015.09.011

(a) IRIS PHARMA, Nice, France 

⇒ Abstract

#2015-189

In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits

QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264

(a) IRIS PHARMA, Nice, France 

⇒ Poster   ⇒ Abstract

#2014-188

The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye

BARABINO S (a), ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b), BOUZIN M (b)

Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548

(a) CLINICA OCULISTICA, GENOCA, ITALY - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2014-185

Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits

VAN DER HEIDEN H (a,b), AMAR T (c), LICHTENAUEUR W (a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 453 - Poster D0072

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France

⇒ Abstract

#2014-184

Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits

QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a), REKIK R (b)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036

(a) IRIS PHARMA, Nice, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia

⇒ Abstract

#2014-182

Biocompatibility of MedinGel biodegradable drug delivery system in the eye

SPIS M (a), FERAILLE L (b), ANTONELLI S (b), CIMBOLINI N (b), ELENA PP (b), GAUDRIAULT G (a), PETIT A (a)

Invest. Ophthalmol. Vis. Sci. 2014;55(13):5273.

(a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2013-179

Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N (a), GRILLO-ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a)

ISOPT meeting 2013; Paris – France

(a) IRIS PHARMA, Nice, France

⇒ Poster

#2013-178

CLS1001 suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), PATEL S (a)

American College of toxicology 2013 San Antonio, Texas - USA. Poster P505

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

#2013-177

Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), PATEL S (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), AMAR T (b), YERXA B (a)

ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

⇒ Abstract

#2012-169

Augmentation of the ocular penetration of dexamethasone with β-blocker and α-agonist co-administration

ELENA PP (a), SENSEBY F (a), BERMON F (a), CHARFEDDINE R (b), REKIK R (c)

EVER meeting 2012; Nice - France. Poster F107

(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

⇒ Abstract

#2012-168

Anti-inflammatory effects of glucocorticoids on endotoxin-induced uveitis in rats: effects of the mode of administration

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D1145

(a) IRIS PHARMA, Nice, France

⇒ Poster   ⇒ Abstract

#2012-167

Assessment of intra-ocular pressure lowering effect of novel gel formulations of latanoprost and timolol in nonhuman primates following topical delivery

GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), BERMON F (b), MARGARON P (b), POLZER H (c), LAWRENCE MS (a)

ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D812

(a) RXGEN, Hamden, CT, USA - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany

⇒ Abstract

#2010-157

Designing dendrimers for ocular delivery

SPATARO G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C (a,b), ELENA PP (d), MAJORAL JP (a,b), CAMINADE AM (a,b)

Eur. J. Med. Chem. 2010; 45: 326-334

(a) CNRS, Laboratoire de Chimie de Coordination, Toulouse, France - (b) Universite de Toulouse, Toulouse, France -  (c) Hôpital Purpan, Toulouse, France - (d) IRIS PHARMA, Nice, France

⇒ Abstract

#2009-156

Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation

AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b), CREAN C (b)

J. Ocul. Pharmacol. Ther. 2009; 25: 433-439

(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE PHARMACEUTICALS, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA

⇒ Abstract

#2009-153

Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations

ELENA PP (a), POLLIN C (a), BERMON F (a), AMAR T (a), CAILLAUD T (a), POLZER H (b)

ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002

(a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany

⇒ Abstract

#2007-148

Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC)

LAMBERT G (a), RABINOVICH-GUILATT L (a)

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO poster No. 2301/B999 (collaboration)

(a) NOVAGALI PHARMA SA, Evry, France

#2007-147

Ocular tolerability of iontophoresis

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), CALIAS P (a)

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800

(a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France

#2007-145

Update on drug delivery systems used in the anterior part of the eye: review of the new drug delivery systems for the anterior chamber

ELENA PP (a)

ESCRS meeting 2007; Stockholm, Sweden. Oral presentation

(a) IRIS PHARMA, Nice, France

#2007-143

A new method for intra ocular pressure in vivo measurement: first clinical trials

DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R, PUECH P

29th IEEE EMBS Annual International Conference 2007; Lyon - France

#2006-131

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits

CAILLAUD T (a), ROY P (b), VIAUD K (a), ELENA PP (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

⇒ Abstract

#2006-130

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate

ROY P (a), VIAUD K (b), CAILLAUD T (b), ELENA PP (b)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110

(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

#2006-129

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits

ELENA PP (a), ROY P (b), VIAUD K (a), CAILLAUD T (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

⇒ Abstract

#2005-124

Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients

RENARD P (a), KOVALSKI JL (b), COCHEREAU I (c), JAULERRY S (d), WILLIAMSON W (e), ELENA PP (f), LABLACHE COMBIER M (g), ALLAIRE C (g), SIOU-MERMET R (g)

Graefe's Arch. Clin. and Exp. Ophthalmol. 2005; 243: 1221-1227

(a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) IRIS PHARMA-CLIROPHTHA, Nice, France - (g) BAUSCH & LOMB, Paris, France

⇒ Abstract

#2004-122

Ocular hypotensive effect of a new “once-daily” eye-dops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol^® 0.5% administered twice-daily

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c), FERREIRA VD (c)

ISOPT meeting 2004; Monte-Carlo – Monaco

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

#2004-121

Intérêt d’une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire

CHIAMBARETTA F (a), CREUZOT-GARCHER C (b), PILON F (a), POULIQUEN P (c), REBIKA H (c), DUBRAY C (d), RIGAL D (a)

J. Fr. Ophtalmol. 2004; 27, 7, 739-744 (collaboration)

(a) Hôpital Gabriel Montpied, Clermont-Ferrand, France - (b) CHU de Dijon, Dijon, France - (C) LABORATOIRES THEA, Clermont-Ferrand, France - (d) Unité de Pharmacologie Clinique, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France

⇒ Article

#2004-120

Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost

BRON A, VELASQUE L, REBICA H, POULIQUEN P, ELENA PP, ROULAND JF

J. Fr. Ophtalmol. 2004; 27(9 Pt 1): 971-7

⇒ Abstract

#2004-119

Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients

ROULAND JF (a), MOREL-MANDRINO P (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c)

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 2080

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy

#2004-118

Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients

ALLAIRE CM, RENARD P, KOVALSKI J, COCHEREAU I, JAULERRY S, WILLIAMSON W, ELENA PP, LABLACHE-COMBIER M

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 957

#2004-117

Efficacy and safety of diclofenac 0.1% ABAK^® versus preserved diclofenac® 0.1% eye drops in controlling post-cataract surgery inflammation

GOLDSCHMIDT P, ELENA PP, BALDWIN H, DELVAL L , COLIN J

ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 294

#2002-112

Timolol 0.1% gel (Nyogel 0.1%^®) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c), SUNDER RAJ P (d)

Ophthalmologica 2002; 216: 449-454

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany - (d) NOVARTIS OPHTHALMICS, Farnborough, UK

⇒ Abstract

#2001-109

A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution

ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c)

IGS meeting 2001; Prague - Czech Republic

(a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany

#2000-106

A new long acting ophthalmic formulation of carteolol containing alginic acid

SECHOY O (a), TISSIE G (a), SEBASTIAN C (a), MAURIN F (a), DRIOT JY (a), TRINQUANT C (a)

Int. J. Pharm. 2000; 207: 109-116 (collaboration)

(a) LABORATOIRE CHAUVIN, Montpellier, France

⇒ Abstract

#2000-105

Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducting the IOP of glaucomatous patients

ELENA PP, ROULAND JF, MOREL-MANDRINO P, POLZER H

ARVO meeting 2000; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2000; 41: S281, abstract No. 2477

#2000-103

Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits

PISELLA PJ (a,b), FILLACIER K (d), ELENA PP (e), DEBBASCH C (b,c), BAUDOUIN C (a)

Ophthalmic Res. 2000; 32: 3-8

(a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France

⇒ Article

#2000-101

Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter

TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, ELENA PP, TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214

#2000-100

Alginic acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits

SEBASTIAN C, TISSIE G, DRIOT JY, ELENA PP, TRINQUAND C

EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215

#1997-86

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits

TILLEUL P, DENIS P, MAIGNEN F, ELENA PP, NORDMANN JP, LEVERGE R, ROSTENE W

Ophthalmic Res. 1997; 29: 218-226

⇒ Abstract

#1996-80

Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model

MAIGNEN F, TILLEUL P, BILLARDON C, XU-VAN OPSTAL WY, PELAPRAT D, ELENA PP, DENIS P, ROSTENE W

J. Ocul. Pharmacol. Ther. 1996; 12: 289-298

#1996-75

Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan^®) in healthy volunteers

POULIQUEN P (a), ELENA PP (b), MALECAZE F (c), LUYCKX J (a), LANOUE A (a), GOLDSCHMIDT P (d)

ARVO meeting 1996; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S313, abstract No. 1431

(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) CLIROPHTHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France

#1996-74

Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, LUYCKX J

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383

#1994-60

Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits

ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J, KHOSRAVI E

ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984

#1993-56

Bioequivalence between timolol maleate formulated in ophthalmic solution (Timoptol®) and in a novel gel vehicle (T-Gel)

ELENA PP, POLZER H, KHOSRAVI E

ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1490, abstract No. 3902

#1993-55

Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium

CHIBRET H, ELENA PP, KHOSRAVI E

ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712

#1992-50

Effect of diclofenac sodium and diclofenac sodium SDU eyedrops on prostaglandin concentrations in aqueous humor of rabbits after extracapsular surgery

ELENA PP, ULRICH E, TSCHALAR Y, LAPALUS P, ETTAICHE M, KHOSRAVI E

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 183

#1992-49

Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit

ELENA PP, KHOSRAVI E, LAPALUS P, ULRICH E

ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182

#2017-211

Transform your macroscope into an ultramacroscope for 3D imaging of cleared organs

GESSON M (a), KECHAD M (b), MAUCLERT N (c), GIRARD P (c), ROUSSEL A (c), PIERRE O (d), GROSJEAN I (e), BRAU F (f)

Focus on Microscopy meeting 2017; Bordeaux - France. Poster No P2-A/26

(a) CNRS, INSERM, Institut Biologie Valrose, Nice, France - (b) IRIS PHARMA, La Gaude, France - (c) OCA, Service de Mécanique Mutualisé, France - (d) IINRA, Institut Sophia Agrobiotech, Biot, France - (e) INSERM, Institut de Recherche sur le Cancer et le Vieillissement, Nice, France - (f) CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France

#2016-205

Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo

FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France

⇒ Article

#2014-186

Regulatory Issues related to preclinical animal research

ELENA PP (a)

ARVO meeting 2014; Orlando, FL - USA. Oral communication

(a) IRIS PHARMA, Nice, France

#2012-175

Report of the TFOS/ARVO symposium on global treatments for dry eye disease: an unmet need

SULLIVAN D (a), HAMMITT K (b), SCHAUMBERG D (c), SULLIVAN B (d), BEGLEY C (e), GJORSTRUP P (f), GARRIGUE JS (g), NAKAMURA M (h), QUENTRIC Y (i), BARABINO S (j), DALTON M (k), NOVACK G (l)

The Ocular Surface. Special Article. April 2012; 10(2): 108-116

(a) SCHEPENS EYE RESEARCH INSTITUTE, Boston, MA, USA - (b) SJOGREN’s SYNDROME FOUNDATION, Bethesda, MD, USA - (c) BRIGHAM AND WOMEN'S HOSPITAL and HARVARD MEDICAL SCHOOL, Boston, MA, USA - (d) TEARLAB Corporation, San Diego, CA, USA - (e) SCHOOL OF OPTOMETRY, Bloomington, IN, USA - (f) RESOLVYX PHARMACEUTICALS, Bedford, MA, USA - (g) NOVAGALI PHARMA, Evry, France - (h) SANTEN PHARMACEUTICAL Co, Nara, Japan - (i) IRIS PHARMA, Nice, France - (j) CLINICA OCULISTICA, Genova, Italy - (k) DALTON & ASSOCIATES, Reading, PA, USA - (l) PHARMA LOGIC, San Rafael, CA, USA

⇒ Abstract

#2011-164

Explorations et imagerie rétinienne

BENCHABOUNE M (a)

STO meeting 2011; Tunis - Tunisia. Oral Communication in French

(a) IRIS PHARMA, Nice, France

#2011-163

Adaptive optics imaging in age-related macular degeneration

GOCHO-NAKASHIMA K (a), BENCHABOUNE M (b), ULLERN M (a), LAMORY B (c), CHATEAU N (c), SAHEL JA (a), PAQUES M (a)

EVER meeting 2011; Crete - Greece. Oral Communication

(a) INSERM 503, Paris, France - (b) IRIS PHARMA, Nice, France - (c) IMAGINE EYES, Orsay, France

⇒ Abstract

#2011-162

In vivo microscopic imaging of drusen using adaptive optics

LAMORY B (a), NAKASHIMA K (b), BENCHABOUNE M (b,c), ULLERN M (b), VUAILLAT E (a), SAHEL JA (b), PAQUES M (b)

ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 4469/A218

(a) IMAGINE EYES, Orsay, France - (b) INSERM 503, Paris, France - (c) IRIS PHARMA, Nice, France

⇒ Abstract

#2010-159

Dry Eye Syndrome: the regulatory challenge. Clinical trial and regulatory challenges faced by Iris Pharma in the development of dry eye therapies

QUENTRIC Y (a)

TFOS Global Dry Eye Experts' meeting 2010; Florence - Italy. Oral Communication

(a) IRIS PHARMA, Nice, France

#2010-158

Rôle des oligoéléments (Se, Zn) dans la prévention de la DMLA : le point en 2010

BENCHABOUNE M (a)

SFVB/SFERETE/ATERET meeting 2010; Monastir - Tunisia. Oral Communication in French

(a) IRIS PHARMA, Nice, France

#2009-155

Associer les patients atteints de DMLA à la recherche, est-ce possible?

BENCHABOUNE M (a)

Vu et Entendu. 2009; 2: 4

(a) IRIS PHARMA, Nice, France

⇒ Article

#2008-150

La recherche biomédicale en France : ce qui a changé depuis 2004

CLERGET-CHOSSAT N (a), CAILLAUD T (a) and ELENA PP (a)

J. Fr. Ophtalmol. 2008; 31: 80-86

(a) IRIS PHARMA, Nice, France

#2007-242

Comparaison in vivo de médicaments anti-allergiques avec  microscope confocal afin d’évaluer la réponse tardive à l’anaphylaxie induit chez le cobaye

FERAILLE L (a)

(a) IRIS PHARMA, Nice, France

#2007-225

Ether-Lipid-Deficient-Mice Display Pigmentary Glaucoma Features as Well as Abnormal Retinal Vasculature

ACAR N (a), SICARD P (b), SCHNEBELEN C (a), CIMBOLINI N (c), IVINGS L (a), GRILLO-ANTONELLI S (c), ROCHETTE L (b), CREUZOT-GARCHER CP (a,d), BRETILLON L (a), JUST WW (e)

(a) INRA, Dijon, France - (b) Faculties of Medicine and Pharmacy, Dijon, France - (c) IRIS PHARMA, Nice, France - (d) University Hospital, Dijon, France - (e) Biochemie Zentrum Heidelberg (BZH), Heidelberg, Germany

#2006-142

The role of the CROs in the ophthalmological drug development in Europe

ELENA PP (a)

Oral presentation. ISOPT meeting 2006; Berlin, Germany

(a) IRIS PHARMA, Nice, France

#1999-249

Learning deficits in first generation OF1 mice deficient in (n-3) polyunsaturated fatty acids do not result from visual alteration

CARRIE I (a), CLEMENT M (a), DE JAVEL D (a), FRANCES H (b), BOURE JM (a) (collaboration)

Neurosci. Lett. 1999; 266: 69-72 doi: 10.1016/S0304-3940(99)00265-7

(a) INSERM U26, Paris, France - (b) Institut de recherche biologique Yves Ponroy, Les Clayes Sous Bois, France

⇒ Abstract

#1996-79

The renin-angiotensin system in the rabbit eye

RAMIREZ M, DAVIDSON EA, LUTTENAUER L, ELENA PP, CUMIN F, MATHIS GA, DE GASPARO M

J. Ocul. Pharmacol. Ther. 1996; 12: 299-312

#1995-67

The renin-angiotensin system in the rabbit eye

RAMIREZ M, DAVIDSON EA, ELENA PP, MATHIS GA, DE GASPARO M

ISECOPP meeting 1995 Geneva - Switzerland, p. 25

#1994-64

Correlation between anterior chamber inflammation and proliferative vitreoretinopathy in the rabbit

KHOSRAVI E, BAUDOUIN C, ELENA PP

JERMOV meeting 1994; Montpellier - France, p 240, abstract No. P192

#1994-63

Central nervous system control of intraocular pressure

DENIS P, NORDMANN JP, ELENA PP, SARAUX H, LAPALUS P

Fundam. Clin. Pharmacol. (France) 1994; 8: 230-237

#1993-57

Physiological roles of dopamine and neuropeptides in the retina

DENIS P, NORDMANN JP, ELENA PP, DUSSAILLANT M, SARAUX H, LAPALUS P

Fundam. Clin. Pharmacol. (France) 1993; 7: 293-304

⇒ Abstract

#1991-47

La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ

DENIS P, ELENA PP, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H, ROSTENE W

"Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113              

#1991-46

Localisation et caractérisation radioautographiques des récepteurs β-adrénergiques oculaires dans les structures non pigmentées chez l'homme

LAPALUS P, ELENA PP, NORDMANN JP, LAROCHE L, SARAUX H, LAPALUS P

Ophtalmologie (France) 1991; 5: 53-56

#1991-45

Localization and characterization of substance P binding sites in rat and rabbit eyes

DENIS P, FARDIN V, NORDMANN JP, ELENA PP, LAROCHE L, SARAUX H, ROSTENE W

Invest. Ophthalmol. Vis. Sci. 1991; 32: 1894-1902

⇒ access to the abstract

#1991-44

Autoradiographic characterization and localization of vasoactive intestinal peptide binding sites in albino rat and rabbit eyes

DENIS P, DUSSAILLANT M, NORDMANN JP, ELENA PP, SARAUX H, ROSTENE W

Exp. Eye Res. 1991; 52: 357-366

⇒ Article

#1991-43

Autoradiographic localization of β-adrenergic binding sites in human retinal blood vessels

DENIS P, ELENA PP, LAPALUS P

Chibret Int. J. 1991; 7: 14-19

#1991-42

Distribution rétinienne des sites récepteurs dopaminergiques rétiniens chez l'homme. Hypothèses fonctionnelles sur le rôle de la dopamine dans la vision

DENIS P, NORDMANN JP, ELENA PP, LAPALUS P

(Dopamine, Fonctions Cérébrales et Neurosensorielles; Budapest - Hungary 1991) Euthérapie

#1990-41

Autoradiographic localization of D1 and D2 dopamine binding sites in the human retina

DENIS P, ELENA PP, NORDMANN JP, SARAUX H, LAPALUS P

Neurosci. Lett. 1990; 116: 81-86

#1990-40

ß-adrenergic binding sites in the human eye: an autoradiographic study

ELENA PP, DENIS P, KOSINA-BOIX M, SARAUX H, LAPALUS P

J. Ocul. Pharmacol. 1990; 6: 143-149

⇒ Abstract

#1990-39

Localisation et caractérisation autoradiographiques de sites de liaison oculaires du VIP (Vasoactive Intestinal Peptide) chez le rat et le lapin albinos

DENIS P, DUSSAILLANT M, ELENA PP, NORDMANN JP, ROSTENE W, LAROCHE L

Ophtalmologie (France) 1990; 4: 30-32

#1990-35

Specific receptors to vasculotropin in the eye

MOUKADIRI H, DENIS P, ELENA PP, ROSTENE W, PLOUET J

AER meeting 1990, Bad Honnef - Germany, p 24, abstract No. 4

#1990-33

Autoradiographic localisation of insulin binding sites in the human eye

DENIS P, ELENA PP, LE MARCHAND-BRUSTEL Y, NORDMANN JP, LAPALUS P, SARAUX H

ISER meeting 1990, Helsinki - Finland, p 114, abstract No. 384

#1990-31

Localisation et caractérisation radioautographiques des récepteurs ß-adrénergiques oculaires dans les structures non pigmentées chez l'homme

DENIS P, ELENA PP, NORDMANN JP, SARAUX H, LAPALUS P

SFO meeting 1990, Paris – France

#1990-30

La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ

DENIS P, ELENA PP, NORDMANN JP, ROSTENE W, LAPALUS P

Séminaires Ophtalmologiques IPSEN, Royaumont - France 1990

#1989-28

Localisation autoradiographique des récepteurs dopaminergiques rétiniens chez l'homme. Implications fonctionnelles

DENIS P, NORDMANN JP, ELENA PP, LAROCHE L, LAPALUS P

Bull. Soc. Ophtalmol. Fr. (France) 1989; 89: 807-810

#1989-27

Récepteurs béta-adrenergiques vasculaires rétiniens chez l'homme

DENIS P, ELENA PP

Ophtalmologie (France) 1989; 3: 62-64

⇒ Abstract

#1989-26

Dopamine receptors in rabbit and rat eye: characterization and localization of DA1 and DA2 binding sites

ELENA PP, DENIS P, KOSINA-BOIX M, LAPALUS P

Curr. Eye Res. 1989; 8: 75-83

⇒ Abstract

#1989-25

Alpha2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography

ELENA PP, KOSINA-BOIX M, DENIS P, MOULIN G, LAPALUS P

Ophthalmic Res. 1989; 21: 309-314

#1989-24

Localisation of angiotensin-converting enzyme (ACE) in rat ciliary process by autoradiography and immunocytochemistry

LALIBERTE F, ELENA PP, LALIBERTE MF, LAPALUS P, CHEVILLARD C

AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 194-195, abstract No. 167

#1989-23

Beta-adrenergic receptors in human eye sections

ELENA PP, DENIS P, LAROCHE L, LAPALUS P

AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 194, abstract No. 166

#1989-22

Autoradiographic localization of vasoactive intestinal peptide binding sites in albino rabbit and rat eye

DENIS P, DUSSAILLANT M, NORDMANN JP, ELENA PP, ROSTENE W, SARAUX H

AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 159-160, abstract No. 104

#1989-21

Autoradiographic localisation of insulin receptors in the human eye

ELENA PP, DENIS P, LE MARCHAND-BRUSTEL Y, LAPALUS P

AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 158-159, abstract No. 102

#1989-18

Piribedil and retinal dopaminergic binding sites

LAPALUS P, ELENA PP, DENIS P, FREDJ-REYGROBELLET D

World Congress of Neurology 1989, New Dehli - India

#1989-17

Localisation autoradiographique des récepteurs dopaminergiques rétiniens chez l'homme. Implications fonctionnelles

DENIS P, NORDMANN JP, ELENA PP, LAROCHE L, LAPALUS P

SFO meeting 1989, Paris - France

#1988-16

Neurotransmitters and intraocular pressure

LAPALUS P, ELENA PP

Fundam. Clin. Pharmacol. (France) 1988; 2: 305-325

#1988-15

Autoradiographic localization of beta-adrenergic binding sites in human blood retinal vessels

ELENA PP, DENIS P, LAPALUS P

ISER meeting 1988, San Francisco, CA - USA

#1988-14

Autoradiographic characterization of D-1 and D-2 receptors in rat, rabbit and human Eyes

ELENA PP, DENIS P, LAPALUS P

ISER meeting 1988, San Francisco, CA - USA

#1987-13

Autoradiographic localization of ß-adrenergic receptors in rabbit eye

ELENA PP (a), KOSINA-BOIX M (b), MOULIN G (a), LAPALUS P (b)

Invest. Ophthalmol. Vis. Sci. 1987; 28: 1436-1441

(a) Laboratoires DULCIS ALLERGAN, Monaco - (b) the Laboratoire de Pharmacologie Faculte de Medecine, Nice, France

⇒ Abstract

#1987-12

Dopamine DA1 receptors in the eye: characterization and localization of 125I-SCH 23982 binding sites

ELENA PP, KOSINA-BOIX M, LAPALUS P

AER meeting 1987, Leuven - Belgium

#1986-10

Monoclonal antibodies to human amnion recognize different components of the rabbit eye

HSI BL, FREDJ-REYGROBELLET D, YEH CJG, ELENA PP, MOULIN G, LAPALUS P

Invest. Ophthalmol. Vis. Sci. 1986; 27: 620-622

⇒ access to the article

#1986-9

Système alpha-adrenergique et pression intra-oculaire

LAPALUS P, ELENA PP

Rencontres Internationales de Chimie Thérapeutique, Clermont-Ferrand - France 1986

#1986-8

Autoradiographic localization of ß-adrenergic receptors in rabbit eye

ELENA PP, KOSINA-BOIX M, MOULIN G, LAPALUS P

AER meeting 1986, Oxford - UK

#1985-7

Embryological studies of rabbit eye by using monoclonal antibodies

FREDJ-REYGROBELLET D, HSI BL, MOULIN G, YEH CJG, ELENA PP, LAPALUS P

AER meeting 1985, Leysin - Switzerland, p 61 abstract No. 73

#1985-6

Alpha-adrenoceptors in rabbit iris-ciliary-body (ICB) membranes: characterization and localization with 3H-clonidine

ELENA PP, PALTRINIERI P, MOULIN G, FREDJ-REYGROBELLET D, LAPALUS P

AER meeting 1985, Leysin - Switzerland, p 56 abstract No. 62

#1984-5

Pharmacological characteristics of β-adrenergic-sensitive adenylate cyclase in non pigmented and pigmented cells of bovine ciliary process

ELENA PP, FREDJ-REYGROBELLET D, MOULIN G, LAPALUS P

Curr. Eye Res. 1984; 3: 1383-1389

#1984-4

Characterization of β-adrenergic receptors in bovine pigmented ciliary processes

ELENA PP, MOULIN G, LAPALUS P

Curr. Eye Res. 1984; 3: 743-750

#1984-1

Adenylate cyclase activity in non pigmented (NPE) and in pigmented (PE) cells of bovine ciliary process

ELENA PP, FREDJ-REYGROBELLET D, MOULIN G, LAPALUS P

ISER meeting 1984, Alicante - Spain, p.95

#1984-232

Wound healing of different epithelia in albino rabbit eye anterior segment

FREDJ-REYGROBELLET D, MOULIN G, ELENA PP, LAPALUS P

ISER meeting 1984, Alicante - Spain, p.95